Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile
Language English Country Germany Media print
Document type Journal Article
PubMed
8586105
DOI
10.1007/bf01736992
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Bone Neoplasms diagnostic imaging secondary MeSH
- Lung Neoplasms diagnostic imaging secondary MeSH
- Thyroid Neoplasms diagnostic imaging pathology MeSH
- Predictive Value of Tests MeSH
- Radionuclide Imaging MeSH
- Sensitivity and Specificity MeSH
- Technetium Tc 99m Sestamibi * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Technetium Tc 99m Sestamibi * MeSH
The aim of the study was to evaluate the possibility of detecting thyroid cancer recurrences without the need for withdrawal of thyroid suppressive treatment. Upper-body or whole-body scintigraphy was performed in a group of 200 patients evaluated for differentiated thyroid cancers in 1993 and 1994 using technetium-99m sestamibi. Scans were performed 20-30min following i.v. administration of 500MBq of 99mTc-methoxyisobutylisonitrile (MIBI). Bone and lung metastases were detected with very high sensitivity and specificity, with a very high predictive value of negative results and a somewhat lower predictive value of positive results. The sensitivity and specificity of findings in the neck were lower but the predictive value of negative results was high. Whole-body scans with 99mTc-MIBI are a useful tool in the follow-up of patients with differentiated thyroid cancer, for the detection of distant metastatic lesions.
See more in PubMed
J Nucl Biol Med. 1992 Oct-Dec;36(4):315-8 PubMed
Ann Acad Med Singapore. 1993 Jul;22(4):557-9 PubMed
Nucl Med Commun. 1995 Aug;16(8):694-7 PubMed
J Nucl Med. 1993 Jan;34(1):71-4 PubMed
J Nucl Med. 1979 Feb;20(2):92-7 PubMed
Eur J Nucl Med. 1994 Sep;21(9):980-3 PubMed
Nuklearmedizin. 1991 Aug;30(4):115-24 PubMed